Evidence-Based Primary Pain Care
A New Opioid Guideline from Washington State

June 12, 2015 • 8 am–5 pm

Bell Harbor International Conference Center, Bay Auditorium
2211 Alaskan Way, Seattle WA 98121

AMDG
agency medical directors’ group

Conference produced by L&I as part of the AMDG.
Designed for primary-care physicians and clinicians, the conference will feature the new 2015 Agency Medical Directors’ Group’s (AMDG’s) Interagency Guideline on Prescribing Opioids for Pain. Hear the latest information on the opioid epidemic, and participate in panel discussions about clinic-friendly practices for safe and effective pain management.

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Lead</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Welcome</td>
<td>Gary Franklin, MD, MPH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kathy Lofy, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>David Tauben, MD</td>
</tr>
<tr>
<td>8:15</td>
<td>The Opioid Epidemic: Overview and a Look to the Future</td>
<td>Chris Jones, PharmD, MPH</td>
</tr>
<tr>
<td></td>
<td>The role of state and federal government and emerging federal policy</td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td>What is the Evidence on the Safety and Effectiveness of Opioids?</td>
<td>Jane Ballantyne, MD</td>
</tr>
<tr>
<td></td>
<td>How is dose related to morbidity and mortality? Defining dependence</td>
<td></td>
</tr>
<tr>
<td></td>
<td>and addiction.</td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td>Highlights of the 2015 AMDG Interagency Guideline on Prescribing</td>
<td>David Tauben, MD</td>
</tr>
<tr>
<td></td>
<td>Opioids for Pain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Will be available in June at <a href="http://www.AgencyMedDirectors.wa.gov">www.AgencyMedDirectors.wa.gov</a></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:15</td>
<td>Non-opioid Treatment Options and Preventing Ineffective Chronic Opioid</td>
<td>Andrew Friedman, MD</td>
</tr>
<tr>
<td></td>
<td>Analgesic Therapy</td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>Prescription Monitoring Program in Washington State</td>
<td>Chris Baumgartner, BS</td>
</tr>
<tr>
<td>11:15</td>
<td>Opioid Use in Patients with Mental Health and Substance Use</td>
<td>Mark Sullivan, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Comorbidities</td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td>Weaning Off Opioids and Initiating Treatment for Opioid Use Disorder</td>
<td>Andy Saxon, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Charissa Fotinos, MD</td>
</tr>
<tr>
<td>12:15</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>1:00</td>
<td>Panel: Lessons from the Front Line – Caring for Chronic Pain Patients</td>
<td>Michael Von Korff, ScD – Moderator</td>
</tr>
<tr>
<td></td>
<td>in the Primary Care Setting</td>
<td>Lucinda Grande, MD</td>
</tr>
<tr>
<td></td>
<td>· How the guideline is used in managing chronic pain patients</td>
<td>Paul Williams, MD</td>
</tr>
<tr>
<td></td>
<td>· How to integrate the PMP into your practice, and triggers for</td>
<td>Patricia Read-Williams, MD</td>
</tr>
<tr>
<td></td>
<td>checking the PMP (e.g. new patient, red flags)</td>
<td>Phillip Capp, MD</td>
</tr>
<tr>
<td></td>
<td>· How to communicate with your patients who have aberrant behaviors</td>
<td></td>
</tr>
<tr>
<td>2:00</td>
<td>Opioids during the Perioperative Period</td>
<td>Greg Terman, MD, PhD</td>
</tr>
<tr>
<td>2:30</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>2:45</td>
<td>Panel: Opioid Use in Special Populations</td>
<td>Dan Lessler, MD – Moderator</td>
</tr>
<tr>
<td></td>
<td>· Pregnancy and Neonatal Abstinence Syndrome</td>
<td>Deb Gordon, RN, DNP, FAAN</td>
</tr>
<tr>
<td></td>
<td>· Pediatrics</td>
<td>Alyssa Stephenson-Famy, MD</td>
</tr>
<tr>
<td></td>
<td>· Older adults</td>
<td>Gary Walco, PhD</td>
</tr>
<tr>
<td></td>
<td>· Cancer survivors</td>
<td>Pam Davies, ARNP, MS, ACHPN</td>
</tr>
<tr>
<td>3:45</td>
<td>Panel: Pain Care Innovations in Health Care Systems</td>
<td>Gary Franklin, MD, MPH – Moderator</td>
</tr>
<tr>
<td></td>
<td>· Group Health</td>
<td>Michael Von Korff, ScD</td>
</tr>
<tr>
<td></td>
<td>· Collaborative Care for Pain</td>
<td>Jeanne Sears, PhD, MS, RN, PHN</td>
</tr>
<tr>
<td></td>
<td>· Everett Clinic</td>
<td>Erica Peavy, MD, CPE</td>
</tr>
<tr>
<td></td>
<td>· VA Pain Care in Patient Aligned Care Team (PACT)</td>
<td>Stephen Hunt, MD, MPH</td>
</tr>
<tr>
<td>4:45</td>
<td>Closing Remarks</td>
<td>Gary Franklin, MD, MPH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>David Tauben, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kathy Lofy, MD</td>
</tr>
<tr>
<td>5:00</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>
Speakers

Jane Ballantyne, MD, Professor (retired), Dept of Anesthesiology and Pain Medicine, University of Washington, Seattle

Chris Baumgartner, BS, Director Prescription Monitoring Program, Dept of Health, Olympia

Philip Capp, MD, Family Medicine, Swedish Medical Center, Seattle

Pamela Davies, ARNP, MS, ACHPN, Pain and Palliative Care Nurse Practitioner, Seattle Cancer Care Alliance; Teaching Associate, University of Washington Dept of Medicine, Seattle

Charissa Fotinos, MD, Deputy Chief Medical Officer, Medicaid Program, Health Care Authority, Olympia

Gary Franklin, MD, MPH, Medical Director, Dept of Labor & Industries; Chair, Washington Agency Medical Directors’ Group; Research Professor, Depts of Environmental and Occupational Health Sciences, Neurology, and Health Services, University of Washington, Olympia and Seattle

Andrew Friedman, MD, Head of Physical Medicine and Rehabilitation, Virginia Mason Medical Center, Seattle

Deb Gordon, RN-BC, MS, DNP, ACNS-BC, FAAN, Clinical Assistant Professor, Dept of Biobehavioral Nursing and Health Systems, University of Washington, Seattle

Lucinda Grande, MD, Clinical Instructor, University of Washington Dept of Family Medicine; Pioneer Family Practice, Lacey

Steve Hunt, MD, MPH, Clinical Associate Professor, University of Washington Dept of Medicine, Occupational and Environmental Medicine; VA Puget Sound Health Care System, Seattle

Christopher Jones, PharmD, MPH, Federal Drug Administration, Washington DC

Dan Lessler, MD, Medical Director, Medicaid, Health Care Authority, Olympia

Kathy Lofy, MD, State Health Officer, Chief Science Officer, Dept of Health, Olympia

Erica Peavy, MD, CPE, Executive Medical Director for Transformation, The Everett Clinic, Everett

Patricia Read-Williams, MD, Clinical Assistant Professor, University of Washington Dept of Family Medicine, Seattle

Andrew Saxon, MD, Professor, Dept of Psychiatry and Behavioral Sciences, University of Washington; Director, Center of Excellence in Substance Abuse Treatment and Education, Veterans Affairs Puget Health Care System, Seattle

Jeanne Sears, PhD, MS, RN, PHN, Research Associate Professor, Dept of Health Services, School of Public Health, University of Washington, Seattle

Alyssa Stephenson-Famy, MD, Assistant Professor, Dept of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of Washington, Seattle

Mark Sullivan, MD, PhD, Professor, Dept of Psychiatry and Behavioral Sciences and Adjunct Professor of Ethics, Bioethics, and Humanities, University of Washington, Seattle

David Tauben, MD, Associate Professor, Depts of Medicine and Anesthesiology and Pain Medicine; Chief, Division of Pain Medicine, University of Washington, Seattle

Greg Terman, MD, PhD, Professor, Dept of Anesthesiology and Pain Medicine, University of Washington; REMS Advisory Committee, National Pain Strategy Oversight Committee and National Pain Strategy Population Research Working Group, Seattle

Michael VonKorff, ScD, Senior Investigator, Group Health Research Institute, Group Health Cooperative, Seattle

Gary Walco, PhD, Chief of Pain Medicine, Seattle Children’s Hospital, Seattle

Paul Williams, MD, Primary Care Physician, Washington Park Direct Care, Centralia, WA

Speakers’ Disclosures

The following conference speakers have had relevant financial relationships and working relationships in the past 12 months:

- Debra Gordon, RN, DNP, FAAN, is on advisory boards for Zogenix, Pazira, and Janssen.
- Lucinda Grande, MD will discuss off-label use of a variety of medications for chronic pain and for opioid withdrawal symptoms.
- Dan Lessler, MD has a relevant financial relationship with Johnson & Johnson, Abbvie, and Pfizer.
- Andrew Saxon, MD is the Editor of Up to Date and will be discussing off-label use of a product and/or an investigational product.
- Alyssa Stephen-Famy, MD will be discussing off-label use of a product and/or an investigational product for pregnant and non-pregnant populations.
- Mark Sullivan, MD, PhD consults for Janssen and develops and disseminates CME on opioids for Opioid REMS program companies.
- David Tauben, MD is a speaker for ER/LA Opioid Analogics REMS Program Companies.
- Michael VonKorff, ScD performs research on opioids for Pfizer, Inc., Campbell Alliance Pharmacy Consortium.
- Gary Walco, PhD is a Pfizer consultant and will be discussing off-label use of a product and/or an investigational product.

Planning Committee

Gary Franklin, MD, MPH
Kathy Lofy, MD
Chris Baumgartner, BS
Michael VonKorff, ScD
Mark Sullivan, MD PhD
Simone Javaheer, RN, BSN, MPA
Jaymie Mai, PharmD
David Tauben, MD
Learning Objectives
After participating in the full conference, participants will be able to:

1. Understand the scientific evidence behind safe opioid prescribing.
2. Prevent opioid dose escalation that can lead to ineffective pain management, hospitalization and death, by learning how to recognize inappropriate and ineffective dosing.
3. Recognize signs and symptoms of patients who are at high risk for poor outcomes with opioids.
4. Properly monitor patients on chronic opioid analgesic therapy (COAT).
5. Apply effective strategies to evaluate pain in a variety of patient populations and stages of pain, and appropriately determine the best way to manage pain while improving function.
6. Prevent unnecessary chronic opioid use by learning about non-opioid options for effective pain management.
8. Apply opioid tapering techniques, when needed.
9. Apply in their practices, the latest information about opioid use, misuse, addiction, and death.
10. Follow state and national recommendations to lessen the epidemic of opioid misuse and abuse.

7.5 AMA PRA Category 1 Credits™
The Department of Labor and Industries (L&I) is accredited by the Washington State Medical Association to provide continuing medical education activities for physicians.

L&I designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity meets the criteria for up to 7.5 hours of Category 1 CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.

**Earning Continuing Medical Education Credits**

**Learning Objectives**
After participating in the full conference, participants will be able to:

1. Understand the scientific evidence behind safe opioid prescribing.
2. Prevent opioid dose escalation that can lead to ineffective pain management, hospitalization and death, by learning how to recognize inappropriate and ineffective dosing.
3. Recognize signs and symptoms of patients who are at high risk for poor outcomes with opioids.
4. Properly monitor patients on chronic opioid analgesic therapy (COAT).
5. Apply effective strategies to evaluate pain in a variety of patient populations and stages of pain, and appropriately determine the best way to manage pain while improving function.
6. Prevent unnecessary chronic opioid use by learning about non-opioid options for effective pain management.
8. Apply opioid tapering techniques, when needed.
9. Apply in their practices, the latest information about opioid use, misuse, addiction, and death.
10. Follow state and national recommendations to lessen the epidemic of opioid misuse and abuse.

**7.5 AMA PRA Category 1 Credits™**
The Department of Labor and Industries (L&I) is accredited by the Washington State Medical Association to provide continuing medical education activities for physicians.

L&I designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity meets the criteria for up to 7.5 hours of Category 1 CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.

**Washington’s Agency Medical Directors’ Group rolls out its new 2015 Opioid Prescribing Guideline* — It’s about more than the dose!**

Only $50 — Register at [eventbright.com](http://eventbright.com)

**Opioid conference**
June 12, 2015 • 8 am – 5 pm

Bell Harbor International Conference Center
Bay Auditorium
2211 Alaskan Way, Pier 66
Seattle WA 98121

- Breakfast, lunch, and refreshments will be provided.
- Free parking in the garage across the street:
  www.bellharbor.com/directions.php

**Please print your own materials**

Before the conference, registrants will receive the speakers’ materials by email. Please print the materials you’d like to have with you at the course. No copies will be available at the conference. You can also follow all of the presentations on your electronic devices.

**Questions?**

- Conference or guideline content:
  Simone.Javaher@Lni.wa.gov or 360-902-4246
- Refunds (available through June 11):
  Denise.Santoyo@Lni.wa.gov or 360-902-5024

*The guideline will be available in June at [www.AgencyMedDirectors.wa.gov](http://www.AgencyMedDirectors.wa.gov).*